Grufity logoGrufity logo

Veracyte Inc Stock Research

VCYT

20.58USD-1.33(-6.07%)Market Closed

Market Summary

USD20.58-1.33
Market Closed
-6.07%

VCYT Alerts

VCYT Stock Price

VCYT RSI Chart

VCYT Valuation

Market Cap

1.5B

Price/Earnings (Trailing)

-40.51

Price/Sales (Trailing)

4.99

EV/EBITDA

-126.73

Price/Free Cashflow

-1.5K

VCYT Price/Sales (Trailing)

VCYT Profitability

EBT Margin

-12.28%

Return on Equity

-3.4%

Return on Assets

-3.16%

Free Cashflow Yield

-0.07%

VCYT Fundamentals

VCYT Revenue

Revenue (TTM)

296.5M

Revenue Y/Y

19.25%

Revenue Q/Q

6.22%

VCYT Earnings

Earnings (TTM)

-36.6M

Earnings Y/Y

63.49%

Earnings Q/Q

55.93%

Price Action

52 Week Range

14.8531.36
(Low)(High)

Last 7 days

-11.5%

Last 30 days

-13.5%

Last 90 days

-12.1%

Trailing 12 Months

-26.0%

VCYT Financial Health

Current Ratio

3.97

VCYT Investor Care

Shares Dilution (1Y)

1.18%

Diluted EPS (TTM)

-0.51

Peers (Alternatives to Veracyte)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
280.3B
58.1B
3.63% 0.47%
23.68
4.83
3.30% 2.55%
88.4B
12.2B
9.24% 19.26%
20.38
7.26
-24.26% -46.28%
80.5B
8.9B
9.01% 22.50%
24.24
9.01
17.91% 41.84%
15.7B
3.4B
-8.71% -10.94%
45.97
4.61
13.67% -64.09%
MID-CAP
6.0B
820.2M
13.45% 34.53%
-11
7.34
31.13% -16.13%
2.6B
278.3M
-25.65% -45.82%
-16.66
9.25
92.72% 15.56%
SMALL-CAP
1.5B
296.5M
-13.46% -26.05%
-40.51
4.99
35.09% 51.62%
589.5M
137.0M
-8.87% -47.72%
-8.78
4.3
45.65% -114.55%
472.7M
321.8M
-38.89% -76.73%
-6.17
1.47
8.57% -149.86%
294.7M
516.3M
-38.46% -85.15%
-0.09
0.57
12.13% -719.59%
252.0M
450.9M
-19.46% -73.63%
16.23
0.56
-3.52% -83.51%
155.1M
-
-11.28% 26.74%
-4.36
-
- -39.92%
3.5M
3.3M
41.75% 90.10%
-0.11
1.07
-21.77% 4.40%

Financials for Veracyte

Income Statement (Last 12 Months)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Revenue4.6%296,536,000283,575,000268,353,000250,594,000219,514,000
  S&GA Expenses2.0%97,560,00095,645,00091,637,00087,298,00079,840,000
  R&D Expenses2.6%40,603,00039,568,00036,801,00033,673,00029,843,000
Costs and Expenses1.8%337,617,000331,569,000323,348,000302,330,000301,417,000
EBITDA43.5%-10,463,000-18,527,000-25,423,000-26,846,000-
EBITDA Margin46.0%-0.04-0.07-0.09-0.11-
Earnings Before Taxes17.8%-36,400,000-44,303,000-50,907,000-50,450,000-81,649,000
EBT Margin21.4%-0.12-0.16-0.19-0.20-
Interest ExpensesInfinity%9,0000.000.0063,0009,000
Net Income15.5%-36,560,000-43,244,000-48,650,000-48,156,000-75,563,000
Net Income Margin19.2%-0.12-0.15-0.18-0.19-
Free Cahsflow20.8%-1,014,000-1,281,000-9,798,000-6,565,000-
Balance Sheet
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Assets2.7%1,1561,1261,1441,1741,188
  Current Assets4.2%249239235238243
    Cash Equivalents-8.9%155170153164173
  Inventory3.6%14.0014.0015.0012.0011.00
  Goodwill2.8%696677690704708
Liabilities4.4%81.0078.0080.0088.0091.00
  Current Liabilities7.3%63.0058.0059.0063.0064.00
    LT Debt, Current-100.0%-1.001.001.001.00
    LT Debt, Non Current------
Shareholder's Equity2.6%1,0751,0481,0641,0851,097
  Retained Earnings-1.0%-393-389-381-371-357
  Additional Paid-In Capital0.5%1,5001,4921,4831,4771,469
Accumulated Depreciation-21.00----
Shares Outstanding0.3%72.0072.0072.0071.0071.00
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Cashflow From Operations20.8%8.006.00-2.180.00-31.62
  Share Based Compensation0.5%27.0027.0027.0025.0023.00
Cashflow From Investing-1044.4%-29.39-2.57-176-166-739
Cashflow From Financing-2.2%3.004.005.007.00596

Risks for VCYT

What is the probability of a big loss on VCYT?

100%


Probability that Veracyte stock will be more than 20% underwater in next one year

70.4%


Probability that Veracyte stock will be more than 30% underwater in next one year.

48.1%


Probability that Veracyte stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does VCYT drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Veracyte was unfortunately bought at previous high price.

Drawdowns

Returns for VCYT

Cumulative Returns on VCYT

21.1%


7-Year Cumulative Returns

29.9%


5-Year Cumulative Returns

-3.9%


3-Year Cumulative Returns

What are the long-term rolling returns for VCYT?

FIve years rolling returns for Veracyte.

Annualized Returns

Which funds bought or sold VCYT recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-03-23
MetLife Investment Management, LLC
unchanged
-
270,584
900,554
0.01%
2023-03-17
American Portfolios Advisors
added
0.59
-28,064
146,379
0.01%
2023-03-10
VICTORY CAPITAL MANAGEMENT INC
sold off
-100
-729,000
-
-%
2023-03-06
Rockefeller Capital Management L.P.
reduced
-83.58
-5,000
1,000
-%
2023-02-28
Voya Investment Management LLC
reduced
-82.58
-1,965,230
651,768
-%
2023-02-24
SRS Capital Advisors, Inc.
new
-
570
570
-%
2023-02-22
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
new
-
515,000
515,000
-%
2023-02-21
NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO
added
0.2
6,778
23,778
-%
2023-02-21
MACQUARIE GROUP LTD
sold off
-100
-4,350,000
-
-%
2023-02-16
HARBOUR INVESTMENTS, INC.
unchanged
-
871
2,871
-%

1–10 of 48

Latest Funds Activity

Are funds buying VCYT calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own VCYT
No. of Funds

Veracyte News

Investor's Business Daily

IBD Rating Upgrades: Veracyte Flashes Improved Relative Price ....

Investor's Business Daily,
6 days ago

Investor's Business Daily

Investor's Business Daily

Investor's Business Daily

Business Wire

Investor's Business Daily

Schedule 13G FIlings of Veracyte

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 09, 2023
william blair investment management, llc
0.8%
558,384
SC 13G/A
Feb 09, 2023
vanguard group inc
9.55%
6,852,657
SC 13G/A
Feb 06, 2023
state street corp
5.80%
4,159,331
SC 13G
Feb 06, 2023
wellington management group llp
9.25%
6,636,543
SC 13G/A
Jan 25, 2023
blackrock inc.
9.1%
6,534,569
SC 13G/A
Feb 14, 2022
nikko asset management americas, inc.
4.39%
3,121,103
SC 13G/A
Feb 10, 2022
invesco ltd.
5.8%
4,114,031
SC 13G/A
Feb 09, 2022
ark investment management llc
11.57%
8,222,281
SC 13G/A
Feb 04, 2022
artisan partners limited partnership
7.0%
4,956,409
SC 13G/A
Feb 04, 2022
wellington management group llp
7.15%
5,078,827
SC 13G

VCYT Fair Value

Veracyte fair value in different scenarios

The table shows the Fair Value estimates for Veracyte for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
Fair ValueVery PessimisticPessimisticBase CaseOptimisticVery Optimistic
Very Low Inflation

4.49

-78.18%

5.39

-73.81%

7.74

-62.39%

10.91

-46.99%

21.36

3.79%
Current Inflation

4.43

-78.47%

5.23

-74.59%

7.28

-64.63%

10.00

-51.41%

18.93

-8.02%
Very High Inflation

4.35

-78.86%

5.04

-75.51%

6.73

-67.30%

8.94

-56.56%

16.11

-21.72%

Historical Veracyte Fair Value Estimates


Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price

Recent SEC filings of Veracyte

View All Filings
Date Filed Form Type Document
Mar 17, 2023
4
Insider Trading
Mar 16, 2023
4
Insider Trading
Mar 15, 2023
144
Notice of Insider Sale Intent
Mar 09, 2023
4
Insider Trading
Mar 09, 2023
4
Insider Trading
Mar 09, 2023
4
Insider Trading
Mar 09, 2023
4
Insider Trading
Mar 03, 2023
4
Insider Trading
Mar 03, 2023
4
Insider Trading
Mar 03, 2023
4
Insider Trading

Latest Insider Trading transactions for VCYT

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-03-16
EASTHAM KARIN
acquired
227,250
12.12
18,750
-
2023-03-16
EASTHAM KARIN
sold
-427,044
22.7757
-18,750
-
2023-03-15
Anderson Bonnie H
acquired
190,740
5.61
34,000
-
2023-03-15
Anderson Bonnie H
sold
-773,888
22.7614
-34,000
-
2023-03-06
Stapley Marc
acquired
-
-
78,044
chief executive officer
2023-03-06
Chambers Rebecca
acquired
-
-
26,014
chief financial officer
2023-03-06
McGuire Annie
acquired
-
-
23,413
svp, general counsel
2023-03-06
Wygant Jonathan
acquired
-
-
8,868
vp, chief accounting officer
2023-03-02
Wygant Jonathan
sold (taxes)
-29,498
24.1
-1,224
vp, chief accounting officer
2023-03-02
Chambers Rebecca
sold (taxes)
-65,696
24.1
-2,726
chief financial officer

1–10 of 50

About Veracyte

VCYT Income Statement

2022-12-31
Consolidated Statements of Operations - USD ($)
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Revenue:   
Total revenue$ 296,536,000$ 219,514,000$ 117,483,000
Operating expenses:   
Research and development40,603,00029,843,00017,204,000
Selling and marketing97,560,00079,840,00052,389,000
General and administrative76,518,000101,353,00036,729,000
Intangible asset amortization21,354,00015,981,0005,095,000
Total operating expenses337,617,000301,417,000152,872,000
Loss from operations(41,081,000)(81,903,000)(35,389,000)
Other income, net4,654,000254,000480,000
Loss before income tax benefit(36,427,000)(81,649,000)(34,909,000)
Income tax provision (benefit)133,000(6,086,000)0
Net loss$ (36,560,000)$ (75,563,000)$ (34,909,000)
Net loss per common share, basic (in USD per share)$ (0.51)$ (1.11)$ (0.66)
Net loss per common share, diluted (in USD per share)$ (0.51)$ (1.11)$ (0.66)
Shares use to compute net loss per common share, basic (in shares)71,549,20467,890,32853,239,231
Shares use to compute net loss per common share, diluted (in shares)71,549,20467,890,32853,239,231
Testing revenue   
Revenue:   
Total revenue$ 250,544,000$ 188,182,000$ 101,970,000
Operating expenses:   
Cost of revenue75,317,00058,860,00035,913,000
Product revenue   
Revenue:   
Total revenue12,632,00011,464,0009,845,000
Operating expenses:   
Cost of revenue7,820,0005,887,0004,921,000
Biopharmaceutical and other revenue   
Revenue:   
Total revenue33,360,00019,868,0005,668,000
Operating expenses:   
Cost of revenue$ 18,445,000$ 9,653,000$ 621,000

VCYT Balance Sheet

2022-12-31
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 154,247$ 173,197
Short-term investments24,6053,964
Accounts receivable44,02141,461
Supplies and inventory14,29411,225
Prepaid expenses and other current assets11,46913,255
Total current assets248,636243,102
Property and equipment, net17,70215,098
Right-of-use assets - operating leases13,16016,043
Intangible assets, net174,866202,731
Goodwill695,891707,904
Restricted cash749749
Other assets5,4182,198
Total assets1,156,4221,187,825
Current liabilities:  
Accounts payable11,91112,360
Accrued liabilities37,77439,475
Current portion of long-term debt01,127
Current portion of deferred revenue2,6134,646
Current portion of acquisition-related contingent consideration6,0602,682
Current portion of operating lease liabilities4,0703,630
Current portion of other liabilities186231
Total current liabilities62,61464,151
Deferred revenue, net of current portion0343
Deferred tax liability4,5315,592
Acquisition-related contingent consideration, net of current portion2,4985,722
Operating lease liabilities, net of current portion10,64814,096
Other liabilities9311,407
Total liabilities81,22291,311
Commitments and contingencies
Stockholders' equity:  
Preferred stock, $0.001 par value; 5,000,000 shares authorized, no shares issued and outstanding as of December 31, 2022 and 202100
Common stock, $0.001 par value; 125,000,000 shares authorized, 71,959,454 and 71,123,108 shares issued and outstanding as of December 31, 2022 and 2021, respectively7271
Additional paid-in capital1,500,1911,468,683
Accumulated deficit(393,717)(357,157)
Accumulated other comprehensive loss(31,346)(15,083)
Total stockholders' equity1,075,2001,096,514
Total liabilities and stockholders' equity$ 1,156,422$ 1,187,825